CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 238 enrolled
Drug / intervention
Ahmed FP7 Valve +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00940823
NCT00940823N/ACompleted
CompareCT.gov

The Ahmed Versus Baerveldt (AVB) Study: Prospective, Multicenter Trial Comparing the Ahmed-FP7 Valve With the Baerveldt-350 Implant in Treating Refractory Glaucoma

Credit Valley EyeCare·interventional·Posted Jul 16, 2009·Updated Mar 13, 2018

In Brief

A clinical study evaluating Ahmed FP7 Valve and Baerveldt-350 Tube for Glaucoma. Completed, enrolled 238 participants across 6 sites in 3 countries.

Detailed Summary

The purpose of this study is to compare the safety and efficacy of the Ahmed valve and the Baerveldt implant in treating refractory glaucoma. Eligible patients will be recruited from multiple study centers and randomized to a glaucoma drainage device for implantation. They will be followed long-term based upon outcome measures including intraocular pressure, glaucoma medication use, visual acuity, complications of the surgery and further treatments required.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesCanada, Chile, United States
CollaboratorsGlaucoma Research Society of Canada

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 16, 2009
Enrollment StartJul 1, 2005
Primary CompletionApr 1, 2014
Study CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 17.0 years ago

Interventions

Ahmed FP7 Valvedevice

Implantation of Ahmed FP7 Valve to lower intraocular pressure in refractory glaucoma.

Baerveldt-350 Tubedevice

Implantation of Baerveldt-350 Tube to lower intraocular pressure in refractory glaucoma.